Biomedicine
Make Drug Administration More Convenient
Zhuhai Creway Pharmaceutical Technology Co., Ltd) is a wholly-owned subsidiary of Youwei (Zhuhai) Biotechnology Co., Ltd., dedicated to the application of dissolving microneedle technology in the field of medicine and medical devices. Creative Pathway = "CREWAY" , implying "innovative drug delivery pathway". Creway is driven by many years of experience in transdermal drug delivery process and formulation research and development, and relies on the independent and original third-generation dissolving microneedle patented preparation technology,the establishment of four platforms "dissolving microneedle preparation research and development platform, sterile pilot industrial production platform, dissolving microneedle detection platform, quality management platform in line with cGMP regulations", development of new transdermal drug delivery products with fewer side effects, better efficacy and better patient compliance.
provides R & D and production services for the global pharmaceutical industry with innovative dosage forms of dissolving microneedles.continuously improves the industrial transformation capacity of soluble microneedle complex preparations, and helps customers realize more breakthrough innovative solutions for drug dosage forms and realize commercial transformation.
Make Drug Administration More Convenient
Zhuhai Creway Pharmaceutical Technology Co., Ltd) is a wholly-owned subsidiary of Youwei (Zhuhai) Biotechnology Co., Ltd., dedicated to the application of dissolving microneedle technology in the field of medicine and medical devices. Creative Pathway = "CREWAY" , implying "innovative drug delivery pathway". Creway is driven by many years of experience in transdermal drug delivery process and formulation research and development, and relies on the independent and original third-generation dissolving microneedle patented preparation technology,the establishment of four platforms "dissolving microneedle preparation research and development platform, sterile pilot industrial production platform, dissolving microneedle detection platform, quality management platform in line with cGMP regulations", development of new transdermal drug delivery products with fewer side effects, better efficacy and better patient compliance.
provides R & D and production services for the global pharmaceutical industry with innovative dosage forms of dissolving microneedles.continuously improves the industrial transformation capacity of soluble microneedle complex preparations, and helps customers realize more breakthrough innovative solutions for drug dosage forms and realize commercial transformation.
Soluble microneedle drug patchgame-changing technology
Soluble microneedle patch technology is a transdermal delivery system that will allow active substances to overcome the skin barrier.it helps to enhance drug delivery through the transdermal/intradermal route,overcome various problems associated with conventional pharmaceutical formulations (oral, injectable, patch).
our drug delivery platform, specialized formulation optimization and optimal drug loading can be performed for drug API and release conditions, and many options are provided for custom design (patch area, microneedle density, microneedle length, etc.). Soluble microneedle technology is considered to be a favorable delivery route for existing vaccines (including influenza, measles-rubella, hepatitis B, etc.) as well as biologics and macromolecular drugs.
Providing core value to pharmaceutical partners
- Provide painless and safe innovative dosage forms
- Applicable to a variety of drug molecules (biological agents, vaccines, macromolecule drugs)
- Can achieve rapid or sustained drug release
- Multi-dimensional customized product design in terms of shape, length, quantity and drug loading of soluble microneedles
- No need for cold chain transportation and storage, which can reduce the difficulty and cost of storage and transportation
- Reduce the medical cost of injection treatment to gain excellent market competitiveness
Provide core value to patients
- Reduce treatment pain and achieve painless drug administration
- Suitable for administration by patients with needle phobia or dysphagia
- Convenient treatment, can be used at home independently, no need for medical staff to operate.
CRO/CDMO Business
Zhuhai Kerui Micro Pharmaceutical Technology Co., Ltd. has built an international leading soluble microneedle pharmaceutical research and development and industrialization platform to provide research and development and production services for the domestic and global pharmaceutical industry. With the business model of CRO CDMO, we continuously improve the industrial transformation capacity of soluble microneedle complex preparations, and help customers realize more breakthrough innovative solutions for drug dosage forms and realize commercial transformation.
CRO/CDMO Business
Zhuhai Kerui Micro Pharmaceutical Technology Co., Ltd. has built an international leading soluble microneedle pharmaceutical research and development and industrialization platform to provide research and development and production services for the domestic and global pharmaceutical industry. With the business model of CRO CDMO, we continuously improve the industrial transformation capacity of soluble microneedle complex preparations, and help customers realize more breakthrough innovative solutions for drug dosage forms and realize commercial transformation.
Phase 1 Feasibility verification and CRO service:(2022-2025)
R & D platform to provide feasibility assessment of soluble microneedle preparations;
sterile pilot industrial production platform for pharmaceutical customers to provide IND declaration, clinical phase 1/2 sample production.
Provides integrated services for pharmaceutical research and development and declaration from IND to NDA.
Phase II CRO CDMO Service (2026 ~)
build a commercial soluble microneedle mass production platform,has the ability to provide customers with clinical phase 3 samples and commercial products commissioned production services.
CDMO Service Scope
Third Generation
Sterile Pilot Industrial Production Platform
- Batch: 5000 paste/batch, 1 batch/2 days
- Non-terminal sterilization production process, equipped with C- level preparation area, B- level background A- level area, cRABS online sterilization system
- Fully automatic aseptic production line (to the completion of aseptic inner packaging)
- Sterile microneedle preparation raw materials, intermediate products and finished products release testing laboratory.